IFLR1000

Lonza Group $5.5 billion acquisition of Capsugel

6/7/2017
Public acquisition
Select tab

$ 5.5 billion

Completed

6/7/2017

Overview:

  • Swiss biotechnology company the Lonza Group has acquired US drug delivery systems producer Capsugel in a $5.5 billion deal.
  • Capsugel was sold by private equity firm KKR.
  • The transaction will be financed through a combination of debt and equity financing.
  • Jefferies, UBS, and Bank of America Merrill Lynch served as financial advisers for the Lonza Group, while Goldman Sachs acted as exclusive financial adviser for Capsugel.

Kurt Stumpo - Journalist

Jurisdictions:

United States
Switzerland

Deal type:

Public acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:
Bär & Karrer

Party: Lonza Group (Acquirer)

Lawyers: Ralph Malacrida, Rolf Watter

Jenner & Block

Party: Lonza Group (Acquirer)

Lawyers: Kevin Collins, Martin Glass

Simpson Thacher & Bartlett

Party: Capsugel (Target)

Lawyers: Clare Gaskell, James Cross, Mark Pflug, Richard Fenyes

Related deals